semaglutide approved for mash 🎉Exciting news that is now FDA (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% Wegovy (semaglutide 2.4 mg) approved

GLP-1 microdosing is a low-dose treatment approach that uses semaglutide or tirzepatide in smaller, carefully guided amounts

The difference is in its indications

The most commonly reported effects include nausea, changes in bowel habits, mild gastrointestinal discomfort, and temporary appetite fluctuations

Early pricing indicated an entry cost of around 49 dollars for the first month, followed by a subscription model of roughly 99 dollars monthly

This table illustrates total and per-dose costs (prices are rounded up to the nearest cent): If you subscribe, your delivery intervals correspond with the quantity you choose: one, three, six, and 12 months, respectively